Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of RSV Vaccine GSK3003891A in Healthy Women
NCT02753413Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Abnormal Biochemical Laboratory Values at Day 30, Number of Subjects With Abnormal Haematological Laboratory Values at Day 30 and 4 more. Started Apr 2016; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02753413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753413.